- Fully enrolled Phase 2b KATALYST-AV trial evaluating ataciguat in aortic stenosis with 156 participants.
- Baseline data consistent with high-risk disease progression markers in real-world cohort.
- Topline Week 48 primary endpoint data expected in 2H 2027 with internal interim analysis at Week 24.
Signal #165046 · SEC 8-K
$KARD SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $KARD filing catalyst
Why did $KARD trigger an AI stock catalyst alert?
$KARD triggered a Stock Catalyst AI alert on 2026-11-06 21:06:32 UTC for a SEC 8-K filing (AI Score: +2.5/10). Headline: Kardigan Completes Phase 2b KATALYST-AV Trial Enrollment, Data Due 2H 2027. Key points: - Fully enrolled Phase 2b KATALYST-AV trial evaluating ataciguat in aortic stenosis with 156 participants. - Baseline data consistent with high-risk disease progression markers in real-world cohort. - Topline Week 48 primary endpoint data expected in 2H 2027 with internal interim analysis at Week 24.
How did $KARD stock react after the SEC filing?
After the SEC 8-K for $KARD, observed market reaction: T0 price $15.52. Past moves do not guarantee future results.
Where can I get real-time $KARD SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $KARD via Telegram and the VIP Web Terminal from €10/month.